Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Oncology

Oncology
Rising incidence across the globe
Cancer is the leading cause of death worldwide. In 2008, it accounted for approximately 7.6 million deaths (~ 13% of all cases). This number is further projected to rise to over 13 million by 2030. The most frequent types of cancer in 2008 were lung (~ 1.6 million new cases), breast (~ 1.4 million new cases), colorectal (~1.2 million new cases) and stomach cancer (~ 1 million new cases).

Combination is key to our approach

Our Oncology franchise is focused on developing novel cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients.
 

Combination is key for us not only in developing products that target multiple aspects of the disease process and are suitable for use in combination with established standard therapies, but also for:

  • Combining innovative thinking with intelligent research and technical excellence ─ our Oncology franchise has brought together a dedicated group of individuals who can look beyond conventional horizons to explore further possibilities. They have the experience and motivation we need to identify potential therapeutic targets and develop novel cancer treatment strategies.
  • Combining insights, experience and skills ─ We are committed to working in partnership with oncology experts, healthcare providers and patients. We strive to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the efficacy of radiotherapy, surgery and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere. 


1Globocan 2008 http://globocan.iarc

Disclaimer

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.

For information on Erbitux, US Residents should consult ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company

  

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.